Ken Fisher’s Vanda Pharmaceuticals VNDA Stock Holding History

Ken Fisher’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-134,792	Closed	-$888K	–	1260
2023 Q2	$888K	Hold	134,792	–	–	﹤0.01%	800
2023 Q1	$915K	Hold	134,792	–	–	﹤0.01%	785
2022 Q4	$996K	Buy	134,792 +32,136	+31%	+$313K	﹤0.01%	772
2022 Q3	$1.01M	Buy	102,656 +33,068	+48%	+$349K	﹤0.01%	664
2022 Q2	$759K	Hold	69,588	–	–	﹤0.01%	651
2022 Q1	$787K	Buy	69,588 +29,786	+75%	+$392K	﹤0.01%	649
2021 Q4	$624K	Buy	+39,802	New	+$694K	﹤0.01%	720

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ken Fisher's VNDA Position: Q3 2023 in Review

Ken Fisher sold out of Vanda Pharmaceuticals (VNDA) in Q3 2023, closing a stake of 134,792 shares — an estimated $888K sold.

Ken Fisher first reported a position in VNDA in Q4 2021 and held it in 7 quarters. The position peaked at $1.01M in Q3 2022. 179 funds tracked by Wall St. Rank hold VNDA as of Q3 2023.

Ken Fisher reported no remaining Vanda Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Ken Fisher sold 134,792 Vanda Pharmaceuticals shares in Q3 2023, an estimated $888K.
Ken Fisher first reported a position in Vanda Pharmaceuticals in Q4 2021 and held it in 7 quarters.
Ken Fisher's Vanda Pharmaceuticals position peaked at $1.01M in Q3 2022.
179 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2023.

Based on Fisher Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.